Senescene-associated exosomal miR-29c reshapes collagen cross‑linking to shift the adipose tissue stiffness sweet spot in aging

Hypothesis

In aged adipose tissue, senescent PDGFRα+ adipose stem cells release exosomes enriched in miR‑29c that suppress collagen III and VI expression while promoting lysyl oxidase–mediated cross‑linking of collagen I. This alters the ECM composition, shifting the intermediate stiffness range that maximizes adipocyte lipid accumulation and oxidative metabolism from ~700–1100 Pa to ~1500–2000 Pa. Consequently, what appears as pathological fibrosis in aging may represent a maladaptive attempt to preserve mechanosignaling for lipid storage under altered matrix composition.

Mechanistic Basis

• Senescent ASC‑derived exosomes deliver miR‑29c to neighboring adipocytes and fibroblasts, downregulating COL3A1 and COL6A1 (see 2 for collagen VI/fibrosis link).
• Reduced collagen III/VI diminishes the formation of compliant, fibrillar networks that normally contribute to the lower‑bound of the optimal stiffness window.
• Concurrently, miR‑29c indirectly upregulates LOX and LOXL2 activity (via suppression of inhibitory pathways), increasing hydroxylysyl aldehyde‑derived cross‑links in collagen I fibrils, thereby raising matrix rigidity without proportional increases in collagen deposition.
• The net effect is a stiffer, more cross‑linked ECM that transmits higher tensile forces to integrin β1 complexes, shifting the set‑point for YAP/TAZ nuclear translocation and downstream PPARγ activation toward higher substrate stiffness.

Predictions & Experimental Design

1. Exosomal miR‑29c levels will be significantly higher in adipose tissue from aged (24‑month) mice versus young (3‑month) mice and correlate with increased LOX activity and reduced COL3A1/COL6A1 mRNA (qPCR, Western blot).
2. In vitro: Treating young PDGFRα+ ASCs with exosomes from senescent ASCs will decrease collagen III/VI deposition and increase collagen I cross‑linking (hydroxylysyl pyridinoline measurement) and raise the stiffness at which lipid uptake peaks (measured by Oil Red O and Seahorse OCR in cultured adipocytes on tunable PEG hydrogels).
3. Loss‑of‑function: Inhibiting miR‑29c in senescent ASCs (antagomiR) or using ASC‑specific Dicer knockout will prevent the shift in the stiffness optimum and exacerbate metabolic dysfunction (glucose intolerance, insulin resistance) in aged mice fed HFD.
4. Gain‑of‑function: Introducing miR‑29c mimics into young ASCs will recapitulate the aged phenotype—higher LOX activity, altered collagen composition, and a rightward shift of the optimal stiffness window.
5. Readouts: Atomic force microscopy (AFM) mapping of tissue modulus, immunofluorescence for phosphorylated YAP, and metabolomic profiling of adipose tissue will verify that the new stiffness range (~1500–2000 Pa) restores PPARγ target gene expression and fatty acid oxidation in aged adipocytes.

Potential Implications

If validated, this hypothesis would re‑frame adipose fibrosis in aging as a mechanobiological adaptation gone awry, suggesting that therapeutic strategies should target exosomal miR-29c/LOX axis rather than generic collagen deposition. It also predicts that the ‘intermediate stiffness sweet spot’ is not a universal constant but is modulated by the collagen cross‑linking landscape, explaining depot‑ and species‑specific variations reported in the literature.

Key References

1 – defines the optimal ECM density range for adipocyte function. 2 – links HIF1α, collagen VI/endotrophin to fibrosis. 3 – describes crown‑like structures and MyD88‑dependent capsule formation. 4 – discusses integrin blockade and mechanotransduction inhibition. 5 – Drosophila model linking cellular imbalance to pericellular collagen trapping. 6 – debates protective vs pathological fibrosis.